## Grigori Joffe

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2769517/publications.pdf

Version: 2024-02-01

331259 360668 1,433 62 21 35 h-index citations g-index papers 66 66 66 1716 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Measurement Invariant but Non-Normal Treatment Responses in Guided Internet Psychotherapies for Depressive and Generalized Anxiety Disorders. Assessment, 2023, 30, 618-632.	1.9	4
2	Internet-Delivered Cognitive Behavioral Therapy for Generalized Anxiety Disorder in Nationwide Routine Care: Effectiveness Study. Journal of Medical Internet Research, 2022, 24, e29384.	2.1	11
3	Mirtazapine in schizophrenia – an undeservedly overlooked option?. International Clinical Psychopharmacology, 2022, 37, 131-142.	0.9	1
4	Scheduled Telephone Support for Internet Cognitive Behavioral Therapy for Depression in Patients at Risk for Dropout: Pragmatic Randomized Controlled Trial. Journal of Medical Internet Research, 2020, 22, e15732.	2.1	14
5	Reducing health inequalities trough digital options in mental health: A physician's perspective. Health Marketing Quarterly, 2019, 36, 93-106.	0.6	9
6	Features of borderline personality disorder as a mediator of the relation between childhood traumatic experiences and psychosis-like experiences in patients with mood disorder. European Psychiatry, 2018, 49, 9-15.	0.1	3
7	Therapeutic alliance in guided internet therapy programs for depression and anxiety disorders $\hat{a}\in$ A systematic review. Internet Interventions, 2018, 11, 1-10.	1.4	108
8	Self-reported treatment adherence among psychiatric in- and outpatients. Nordic Journal of Psychiatry, 2018, 72, 526-533.	0.7	7
9	Identifying Local and Centralized Mental Health Servicesâ€"The Development of a New Categorizing Variable. International Journal of Environmental Research and Public Health, 2018, 15, 1131.	1.2	14
10	A Comparison of Mental Health Care Systems in Northern and Southern Europe: A Service Mapping Study. International Journal of Environmental Research and Public Health, 2018, 15, 1133.	1.2	40
11	Relationships between self-reported childhood traumatic experiences, attachment style, neuroticism and features of borderline personality disorders in patients with mood disorders. Journal of Affective Disorders, 2017, 210, 82-89.	2.0	38
12	Psychoactive substance use in specialized psychiatric care patients. International Journal of Psychiatry in Medicine, 2017, 52, 399-415.	0.8	7
13	Add-on mirtazapine improves orgasmic functioning in patients with schizophrenia treated with first-generation antipsychotics. Nordic Journal of Psychiatry, 2017, 71, 77-80.	0.7	9
14	Regional Correlates of Psychiatric Inpatient Treatment. International Journal of Environmental Research and Public Health, 2016, 13, 1204.	1.2	7
15	How size matters: exploring the association between quality of mental health services and catchment area size. BMC Psychiatry, 2016, 16, 289.	1.1	12
16	Patient Experience of Coercive Measures. , 2016, , 255-270.		7
17	Short report: self-reported psychopathic traits in Finnish and Dutch samples of non-referred adolescents: exploration of cultural differences. Child and Adolescent Psychiatry and Mental Health, 2016, 10, 3.	1.2	2
18	Differences and similarities of risk factors for suicidal ideation and attempts among patients with depressive or bipolar disorders. Journal of Affective Disorders, 2016, 193, 318-330.	2.0	70

#	Article	IF	CITATIONS
19	Is there an interrelationship between the effects of antipsychotics on psychopathology and on metabolism?. Nordic Journal of Psychiatry, 2016, 70, 190-194.	0.7	7
20	Randomized Controlled Trials of Add-On Antidepressants in Schizophrenia. International Journal of Neuropsychopharmacology, 2015, 18, pyv049.	1.0	27
21	Lithium is associated with decrease in all-cause and suicide mortality in high-risk bipolar patients: A nationwide registry-based prospective cohort study. Journal of Affective Disorders, 2015, 183, 159-165.	2.0	58
22	Size Matters â€" Determinants of Modern, Community-Oriented Mental Health Services. International Journal of Environmental Research and Public Health, 2014, 11, 8456-8474.	1.2	17
23	Does Primary Care Mental Health Resourcing Affect the Use and Costs of Secondary Psychiatric Services?. International Journal of Environmental Research and Public Health, 2014, 11, 8743-8754.	1.2	12
24	eLearning course may shorten the duration of mechanical restraint among psychiatric inpatients: A cluster-randomized trial. Nordic Journal of Psychiatry, 2014, 68, 443-449.	0.7	24
25	Toward a Safer Working Environment on Psychiatric Wards: Service Users' Delayed Perspectives of Aggression and Violence-Related Situations and Development Ideas. Perspectives in Psychiatric Care, 2014, 50, 271-279.	0.9	21
26	Methodological and ethical challenges in studying patients' perceptions of coercion: a systematic mixed studies review. BMC Psychiatry, 2014, 14, 162.	1.1	21
27	Psychiatric staff on the wards does not share attitudes on aggression. International Journal of Mental Health Systems, 2014, 8, 14.	1.1	17
28	Impact of eLearning course on nurses' professional competence in seclusion and restraint practices: 9â€month followâ€up results of a randomized controlled study (ISRCTN32869544). Journal of Psychiatric and Mental Health Nursing, 2013, 20, 411-418.	1.2	12
29	Does experienced seclusion or restraint affect psychiatric patients' subjective quality of life at discharge?. International Journal of Mental Health Systems, 2013, 7, 28.	1.1	20
30	Mechanical restraint in adolescent psychiatry: A Finnish Register study. Nordic Journal of Psychiatry, 2013, 67, 132-139.	0.7	16
31	Secluded and restrained patients' perceptions of their treatment. International Journal of Mental Health Nursing, 2013, 22, 47-55.	2.1	42
32	Predictors and mediators of add-on mirtazapine-induced cognitive enhancement in schizophrenia $\hat{a} \in A$ path model investigation. Neuropharmacology, 2013, 64, 248-253.	2.0	8
33	In a randomized placebo-controlled add-on study orlistat significantly reduced clozapine-induced constipation. International Clinical Psychopharmacology, 2013, 28, 67-70.	0.9	22
34	Influence of patient characteristics on duration of seclusion/restrain in acute psychiatric settings in <scp>J</scp> apan. Psychiatry and Clinical Neurosciences, 2013, 67, 405-411.	1.0	36
35	Relationships between pharmacotherapy-induced metabolic changes and improved psychopathology in schizophrenia: data from a mirtazapine and first-generation antipsychotics combination trial. International Journal of Neuropsychopharmacology, 2013, 16, 1661-1666.	1.0	7
36	Antidepressants in Schizophrenia: A Place for Them?. , 2013, , 211-231.		0

#	Article	IF	Citations
37	Underaged Patients' Opinions Toward Different Containment Measures: A Questionnaire Survey in <scp>F</scp> innish Adolescent Psychiatry. Journal of Child and Adolescent Psychiatric Nursing, 2012, 25, 219-223.	0.8	7
38	Seclusion and Restraint in Psychiatry: Patients' Experiences and Practical Suggestions on How to Improve Practices and Use Alternatives. Perspectives in Psychiatric Care, 2012, 48, 16-24.	0.9	146
39	Attitudes towards different containment measures: a questionnaire survey in Finnish adolescent psychiatry. Journal of Psychiatric and Mental Health Nursing, 2012, 19, 521-527.	1.2	9
40	Factors affecting assessment of severity of aggressive incidents: using the Staff Observation Aggression Scale – Revised (SOASâ€R) in Japan. Journal of Psychiatric and Mental Health Nursing, 2012, 19, 770-775.	1.2	5
41	Secluded/restrained patients' perceptions of their treatment: Validity and reliability of a new questionnaire. Psychiatry and Clinical Neurosciences, 2012, 66, 397-404.	1.0	3
42	More evidence on proneurocognitive effects of add-on mirtazapine in schizophrenia. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2011, 35, 1080-1086.	2.5	21
43	Impact of eLearning course on nurses' professional competence in seclusion and restraint practices: a randomized controlled study (ISRCTN32869544). Journal of Psychiatric and Mental Health Nursing, 2011, 18, 813-821.	1.2	25
44	Addâ€on mirtazapine improves depressive symptoms in schizophrenia: a doubleâ€blind randomized placeboâ€controlled study with an openâ€label extension phase. Human Psychopharmacology, 2011, 26, 188-193.	0.7	24
45	Orlistat in Clozapine- or Olanzapine-Treated Patients With Overweight or Obesity. Journal of Clinical Psychiatry, 2011, 72, 326-330.	1.1	32
46	Effects of add-on mirtazapine on neurocognition in schizophrenia: a double-blind, randomized, placebo-controlled study. International Journal of Neuropsychopharmacology, 2010, 13, 433.	1.0	25
47	More evidence on additive antipsychotic effect of adjunctive mirtazapine in schizophrenia: an extension phase of a randomized controlled trial. Human Psychopharmacology, 2010, 25, 431-438.	0.7	21
48	Patient restrictions: Are there ethical alternatives to seclusion and restraint?. Nursing Ethics, 2010, 17, 65-76.	1.8	81
49	STAFF ATTITUDES TOWARDS SCHIZOPHRENIA, WARD ATMOSPHERE AND THE USE OF SECLUSION AND RESTRAINT. Schizophrenia Research, 2010, 117, 406-407.	1.1	0
50	Add-On Filgrastim During Clozapine Rechallenge in Patients With a History of Clozapine-Related Granulocytopenia/Agranulocytosis. American Journal of Psychiatry, 2009, 166, 236-236.	4.0	26
51	Nurses' and Physicians' Educational Needs in Seclusion and Restraint Practices. Perspectives in Psychiatric Care, 2009, 45, 198-207.	0.9	15
52	Add-on mirtazapine enhances antipsychotic effect of first generation antipsychotics in schizophrenia: A double-blind, randomized, placebo-controlled trial. Schizophrenia Research, 2009, 108, 245-251.	1.1	56
53	The effectiveness of technology-based patient education on self-reported deprivation of liberty among people with severe mental illness: A randomized controlled trial. Nordic Journal of Psychiatry, 2009, 63, 383-389.	0.7	19
54	Shift from first generation antipsychotics to olanzapine may improve health-related quality of life of stable but residually symptomatic schizophrenic outpatients: A prospective, randomized study. International Journal of Technology Assessment in Health Care, 2008, 24, 399-402.	0.2	4

#	Article	IF	CITATIONS
55	Orlistat in Clozapine- or Olanzapine-Treated Patients With Overweight or Obesity. Journal of Clinical Psychiatry, 2008, 69, 706-711.	1.1	59
56	Altered Expression of Myeloperoxidase Precursor, Myeloid Cell Nuclear Differentiation Antigen, Fms-related Tyrosine Kinase 3 Ligand, and Antigen CD11A Genes in Leukocytes of Clozapine-treated Schizophrenic Patients. Journal of Clinical Psychopharmacology, 2006, 26, 335-338.	0.7	2
57	Topiramate Add-On in Treatment-Resistant Schizophrenia. Journal of Clinical Psychiatry, 2005, 66, 1012-1015.	1.1	86
58	Is it worth while changing clinically stable schizophrenic out-patients with mild to moderate residual symptoms and/or side effects from conventional to atypical antipsychotics? A prospective, randomised study with olanzapine. European Psychiatry, 2004, 19, 516-518.	0.1	17
59	Decreased Production of Reactive Oxygen Species by Blood Monocytes Caused by Clozapine Correlates with EEG Slowing in Schizophrenic Patients. Neuropsychobiology, 2003, 47, 73-77.	0.9	12
60	Clozapine-induced decrease in the production of reactive oxygen metabolites by monocytesin vitro may predict clinical response to clozapine in treatment-resistant schizophrenia. Human Psychopharmacology, 1999, 14, 203-209.	0.7	0
61	Is there an association between the effects of clozapine on the production of reactive oxygen metabolites by blood monocytes and clinical outcome in neuroleptic-resistant schizophrenia?. Human Psychopharmacology, 1998, 13, 231-237.	0.7	3
62	Clozapine response in early treatment-resistant schizophrenia. International Journal of Psychiatry in Clinical Practice, 1997, 1, 261-268.	1.2	3